Your browser doesn't support javascript.
loading
SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021).
Capdevila, Jaume; Gómez, Ma Auxiliadora; Guillot, Mónica; Páez, David; Pericay, Carles; Safont, Maria José; Tarazona, Noelia; Vera, Ruth; Vidal, Joana; Sastre, Javier.
Affiliation
  • Capdevila J; Department of Medical Oncology, Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain. jacapdevila@vhebron.net.
  • Gómez MA; Department of Medical Oncology, Hospital Universitario Reina Sofía. IMIBIC. CIBERONC, Córdoba, Spain.
  • Guillot M; Department of Medical Oncology, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
  • Páez D; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau. U705. CIBERER, Barcelona, Spain.
  • Pericay C; Department of Medical Oncology, Hospital Universitari Mútua de Terrassa, Terrassa, Spain.
  • Safont MJ; Department of Medical Oncology, Consorcio Hospital General Universitario de Valencia, Universidad de Valencia. CIBERONC, Valencia, Spain.
  • Tarazona N; Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Vera R; Instituto de Salud Carlos III, CIBERONC, Madrid, Spain.
  • Vidal J; Department of Medical Oncology, Hospital Universitario de Navarra; Navarrabiomed, IDISNA, Pamplona, Spain.
  • Sastre J; Department of Medical Oncology, Hospital del Mar-IMIM, CIBERONC, Barcelona, Spain.
Clin Transl Oncol ; 24(4): 646-657, 2022 Apr.
Article de En | MEDLINE | ID: mdl-35303269
ABSTRACT
The management of localized rectal cancer requires a multidisciplinary approach to optimize outcomes, reduce morbidity and prevent under or overtreatments. While early stages may obtain benefit of local resections without any additional therapies, locally advanced rectal cancer becomes a challenge defining the better sequential strategy of surgery, radiotherapy and chemotherapy. The latest results of international phase III studies have positioned the total neoadjuvant therapy as a potential new standard of care in high risk rectal cancers, however, the best schedule is still not well defined.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du rectum / Seconde tumeur primitive Type d'étude: Guideline Limites: Humans Langue: En Journal: Clin Transl Oncol Année: 2022 Type de document: Article Pays d'affiliation: Espagne

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du rectum / Seconde tumeur primitive Type d'étude: Guideline Limites: Humans Langue: En Journal: Clin Transl Oncol Année: 2022 Type de document: Article Pays d'affiliation: Espagne